基于肠-肾轴理论浅析膳食纤维对慢性肾病的影响

慢性肾病(chronic kidney disease,CKD)可引起肠道菌群失调及肠道屏障功能受损,而肠道稳态的破坏有 利于肠源性毒素的产生及肠腔细菌、内毒素的易位,加重CKD的尿毒症毒性及全身性炎症。膳食纤维可靶向作用于 “肠-肾轴”,从而降低CKD的尿毒症毒素水平及减轻全身性炎症。膳食纤维有望成为治疗CKD的新策略。     

颅脑肿瘤手术行急性等容血液稀释的临床研究

目的：研究急性等容血液稀释对颅脑肿瘤病人血流动力学、氧转运及凝血纤溶方面的影响,探讨该方法的安全性。方法：选择颅脑肿瘤手术病人12例,麻醉后从右颈内静脉放置Swan～Ganz导管,从桡动脉放血8ml/kg,同时等速从静脉输入等量的海脉素。分别测定血液稀释前后的血流动力学,氧转运及凝血纤溶方面的指标。结果：CO、SV、DO2显著增加(P＜0.05);PT延长(P＜0.05);PLT较血液稀释前减少,其余指标无明显改变。结论：急性等容血液稀释对颅脑肿瘤病人的血流动力学及凝血纤溶功能影响小,而氧供增加,是一安全有效的血液保护方法。     

胆汁泡蛋白ELISA检测法的建立与初步临床应用

目的 建立胆汁泡蛋白快速检测法,筛选有效的胆石症防治手段。方法 获取３３．５ｋｄ胆汁泡蛋白,通过微量抗原免疫法获得高效价抗体,建立ＥＬＩＳＡ标准曲线;并应用ＥＬＩＳＡ法测定正常人、胆石症患者胆汁和血清中泡蛋白含量,同时观察不同溶石防药和利胆冲剂、胆酸钠等对泡蛋白的影响。结果 建立了ＥＬＩＳＡ标准曲线,其曲线方程为Ｙ＝０．０３５Ｘ（ｒ＝０．９９）;正常人胆汁和血清中３３．５ｋｄ泡蛋白含量都明显较胆固     

北京市一些高级办公大楼室内空气质量问题探讨

我们调查了北京一些高档的空调建筑,包括商业和政府机构办公大楼,测试了主要的室内污染和室内气象参数,如温度、湿度、风速等。测试结果指出,在这些建筑中存在着严重的室内空气质量问题。而且,引起不良室内空气质量的原因不是单一的而是多方面的。因此如何提高室内空气质量,为人们提供健康而舒适的室内环境,是空调设计者的迫切任务。     

缺血性脑血管病患者用天新利博前后血小板聚集的变化

目的探讨天新利博对缺血性脑血管病(ICVD)患者血小板聚集影响的程度.方法比浊法测定12例ICVD患者治疗前后,用二种诱聚剂诱导的血小板聚集率.结果(-x±S)ICVD组用药后第5天、第10天ADP诱导血小板聚集率(32.87%±14.2%,44.99%±12.3%)显著低于用药前(71.9%±11.1%)P<0.01;Adr诱导的血小板聚集率与用药前比较则无显著性差异(P>0.05).结论天新利博对ICVD患者ADP诱导的血小板聚集有明显抑制作用,对Adr诱导的血小板聚集无影响.监测其血小板聚集率时,应选用ADP作为诱聚剂.     

脑梗塞患者脂蛋白(A)水平与肾脏早期损害

为探讨脑梗塞患者脂蛋白（Ａ）水平与肾脏早期损害的关系,应用ＥＬＩＳＡ法及化学显色终点法分别检测４０例梗塞患者血清ＬＰ（Ａ）水平和尿氨基葡萄糖苷酶活力。结果表明,脑梗塞组血ＬＰ（Ａ）及ＮＡＧ均明显高于正常对照组,且ＬＰ（Ａ）值与尿ＮＡＧ活力呈正相关。     

430名新疆哈萨克族成人同身寸长度与身高关系的研究

目的：研究新疆哈萨克族成人同身寸长度与身高的关系,为人类学、法医学研究以及针灸取穴提供基础资料。方法：应用 Ｈｒｄｌｉｃｋａ 标准和我国普遍采用的方法测量了４３０ 名（男１９７ 名,女２３３ 名）新疆哈萨克族成人同身寸长和身高。结果：按性别和年龄分组,计算出各组同身寸的均值、身高的均值及身高与同身寸的比值,并提出了由同身寸推算身高的回归方程。结论：通过同身寸长可推算身高,同身寸长和身高有显著性的直结回归关系。     

利培酮与氯氮平治疗首发精神分裂症的对照研究

目的：比较利培酮和氯氮平治疗首发精神分裂症的有效性和安全性。方法：６０例ＢＰＲＳ总分≥４０分,符合ＣＣＭＤ－２－Ｒ精神分裂症诊断标准的患者,随机分为两组进行对照研究,分别给予利培酮和氯氮平口服治疗,以ＢＰＲＳ减分率为疗效评定指标,以ＴＥＳＳ评价副反应指标。结果：利培酮治疗首发精神分裂症疗效肯定,８周末有效率为９０％,与氯氮平相仿。利培酮在治疗１周后起效,焦虑、抑郁和迟滞等症状群起效更早,明显早于氯氮平。剂量较小者锥体外系副反应轻,其它不良副反应发生率和严重程度均较氯氮平少而轻。结论：利培酮是治疗精神分裂症有效、安全的一线抗精神病药物     

CT 对腮腺区肿块的诊断价值

评价ＣＴ对腮腺肿瘤的诊断价值。方法８８例腮腺区肿瘤进行ＣＴ平扫,ＣＴ增强扫描和／或腮腺造影ＣＴ扫描。结果：７８例为腺内肿瘤,其中７例为恶性;１０例为腺肿瘤。对ＣＴ肋腺区肿瘤定位准确,能准确显示肿瘤的范围,大小,数目及浸润情况。     

Duration and recovery profile of cisatracurium after succinylcholine during propofol or isoflurane anesthesia

Study Objective: To determine the duration and recovery profile of maintenance doses of cisatracurium besylate following succinylcholine, and during propofol or isoflurane anesthesia.

Design: Randomized, open-label study.

Setting: Operating suite of a university-affiliated medical center.

Patients: Forty ASA physical status I and II adult patients having elective surgery with general anesthesia lasting longer than 90 minutes.

Interventions: Following a standardized induction sequence, a baseline electromyogram (EMG) was obtained. An intubating dose of intravenous (IV) succinylcholine 1.0 mg/kg was administered. Ventilation was maintained with a face mask until the first twitch (T₁) of the evoked train-of-four (TOF) reached 10% of control when tracheal intubation was performed. Spontaneous recovery from neuromuscular blockade was allowed to occur until the first twitch returned to 25% of control. Patients then were randomized to receive cisatracurium as follows. Group 1: 0.025 mg/kg [0.5 × 95% effective dose (ED₉₅)]; Group 2: 0.05 mg/kg (ED₉₅); Group 3: 0.05 mg/kg (ED₉₅); and Group 4: 0.1 mg/kg (2×ED₉₅). Anesthesia for Groups 1 and 2 were maintained with isoflurane 1% to 2%, 66% nitrous oxide (N₂O) in oxygen (O₂), and in Groups 3 and 4, anesthesia was maintained with propofol 80 to 160 μg/kg/min, 66% N₂O in O₂. The TOF-evoked EMG was recorded at 10-second intervals. The time for the evoked EMG to spontaneously return to 25%, 50%, and 75% of the original baseline was recorded.

Measurements and Main Results: There were 10 patients in each of the four groups. The duration of action of cisatracurium 0.05 mg/kg (ED₉₅) after an intubating dose of succinylcholine is 24.5 ± 10 minutes and 21.3 ± 9 minutes during anesthesia maintained with isoflurane and propofol, respectively. Doubling the dose of cisatracurium resulted in approximately twice the duration of action (40.2 ± 7 min) during propofol anesthesia. Following a dose of cisatracurium 0.025 mg/kg (0.5×ED₉₅), the T₁ of the EMG-evoked response did not decrease below 25% in 7 of 10 patients.

Conclusion: Following succinylcholine, the duration of action of a single dose of cisatracurium 0.05 mg/kg is 20 to 25 minutes during anesthesia maintained with propofol or isoflurane. The duration and recovery profile of cisatracurium is dose dependent during propofol and isoflurane anesthetics. Cisatracurium 0.025 mg/kg is an inadequate maintenance dose following recovery from succinylcholine and it fails to provide adequate surgical relaxation.